Sign In
Buy MBOT
$1.72
-0.0200 (-1.15%)
At Close: Jul 31, 2026
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
08:30am, Tuesday, 24'th Feb 2026
HINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa Ge
Microbot Medical®'s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference
Microbot Medical®'s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
08:30am, Thursday, 12'th Feb 2026
International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY® Continues to Gain Commercial Traction and
HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it is attendin
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
08:30am, Monday, 12'th Jan 2026
Limited Market Release (LMR) of the LIBERTY® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGH
HINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
08:30am, Wednesday, 05'th Nov 2025
Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership Interest a
Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)
10:36am, Wednesday, 29'th Oct 2025
Microbot Medical (MBOT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
08:30am, Thursday, 16'th Oct 2025
First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
08:30am, Tuesday, 14'th Oct 2025
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 Th
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upo
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
09:00am, Wednesday, 01'st Oct 2025
Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increas
All You Need to Know About Microbot Medical (MBOT) Rating Upgrade to Buy
01:00pm, Friday, 26'th Sep 2025
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
08:30am, Tuesday, 23'rd Sep 2025
Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term prefer
